Pharmaceutical - Pharmaceutical, Pharmacyclics

Filter

Popular Filters

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

13-02-2014

The US Food and Drug Administration yesterday expanded the approved use of US health care giant Johnson…

ImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics signs deal with Lonza to support manufacturing of Imbruvica

Pharmacyclics signs deal with Lonza to support manufacturing of Imbruvica

13-01-2014

USA-based Pharmacyclics has signed a deal with Swiss chemical supplier Lonza for the commercial and clinical…

ImbruvicaLonzaOncologyPharmaceuticalPharmacyclicsProductionUSA

Janssen and Pharmacyclics’ Imbruvica meets key endpoints early in Phase III leukemia trial

Janssen and Pharmacyclics’ Imbruvica meets key endpoints early in Phase III leukemia trial

08-01-2014

USA-based Pharmacyclics and co-developer Janssen Biotech have announced that an Independent Data Monitoring…

ImbruvicaJanssen BiotechOncologyPharmaceuticalPharmacyclicsResearchUSA

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

14-11-2013

The US Food and Drug Administration yesterday approved US health care giant Johnson & Johnson’s Imbruvica…

ibrutinibImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclics

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Study of mechanism of ibrutinib action in mantle cell lymphoma

22-08-2013

A study that investigated the mechanism of ibrutinib's anti-tumor effect in patients with mantle cell…

ibrutinibJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Janssen submits NDA for "breakthrough" leukemia and lymphoma drug ibrutinib

11-07-2013

Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), has submitted…

ibrutinibJanssen PharmaceuticaJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

16-06-2013

Among presentations over the weekend at the Congress of European Hematology Association (EHA) being held…

AbbVieBristol-Myers SquibbelotuzumabibrutinibIncyteJakaviJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data

09-04-2013

Pharmacyclics (Nasdaq: PCYC) saw its shares gain 4.5% to $78.96 in early trading Monday, after it revealed…

ibrutinibJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib

14-02-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib

11-12-2012

During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

Pharmacyclics gets second $50 million milestone from Janssen

21-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress

03-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

19-02-2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC)…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalPharmacyclics

Highlights of ASH meeting

13-12-2011

Among presentations at this year’s Annual Meeting of the American Society of Hematology (ASH), held…

AEterna ZentarisAriad PharmaceuticalsBiotechnologyblinatumomabMicrometOncologyperifosinePharmaceuticalPharmacyclicsponatinibResearch

J&J to pay nearly $1 billion for cancer drug candidate

09-12-2011

US health care giant Johnson & Johnson (NYSE: JNJ), through its subsidiary Janssen Biotech, has executed…

Janssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalPharmacyclics

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top